Kala Pharmaceuticals Announces FDA Acceptance Of IND Application For KPI-012 For The Treatment Of PCED; Received Remaining $25M Investment Under Previously Announced Private Placement Financing
On-track to initiate Phase 2b trial in 1Q 2023; Topline data expected in 1Q 2024 --
-- Received remaining $25 million investment under previously announced private placement financing --